As a consequence, the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel undertook an international collaborative study involving healthcare practitioners and patients to develop consensus statements for deferred treatment with curative intent for localised PCa, covering all domains of AS (DETECTIVE Study) [DETECTIVE did agree that men with favourable ISUP 2 cancer (PSA < 10 ng/mL, clinical stage [The DETECTIVE consensus group were clear that those with ISUP 3 disease should not be considered. These nomograms require further validation, but in due time they may out-perform predictors such as the current risk calculators (e.g. = not reported; OS = overall survival; RP = radical prostatectomy.The SPCG-4 study randomised patients to either WW or RP (Table 6.1.3) [Table 6.1.3: Outcome of SPCG-4 at 15-year follow-up CI = confidence interval; n.r. not as pT4, because it does not carry independent prognostic significance for PCa recurrence [Stage pT4 is only assigned when the tumour invades the bladder muscle wall as determined macroscopically [The independent prognostic value of PCa volume in RP specimens has not been established [Surgical margin is an independent risk factor for BCR. These should be performed at 3, 6 and 12 months after treatment, then every 6 months until 3 years, and then annually.At recurrence, only perform imaging to detect local recurrence if the outcome will affect treatment planning.Only offer bone scans and other imaging modalities to men with biochemical recurrence or symptoms suggestive of progression without signs of biochemical relapse.Follow-up must be individualised as a rising PSA might be associated with rapid symptomatic progression or evolve without progression on imaging or symptoms over time. No difference in terms of side-effects was observed in the two groups, with a lower incidence of grade 3-4 adverse events in the enzalutamide arm. However, no studies showed an increase in adverse oncologic outcome or complications with reconstruction.For EAU Guidelines recommendations on post-RP deep venous thrombosis prophylaxis, please see the Thromboprophylaxis Guidelines Section 3.1.6 [Table 6.1.5: Intra-and peri-operative complications of retropubic RP and RALP (Adapted from RALP = robot-assisted laparoscopic prostatectomy; RP = radical prostatectomy; RRP = radical retropubic prostatectomy.Pelvic eLND increases morbidity in the treatment of PCa [Currently, three large prospective RCTs have compared RP over deferred treatment (see Section 6.1.2). However, these findings were not associated with any survival benefit and in a recent The potential toxicity (e.g., osteonecrosis of the jaw, hypocalcaemia) of these drugs must always be kept in mind (5-8.2% in M0 CRPC and mCRPC, respectively) [Hypocalcaemia should be identified and prevented during treatment with bone protective agents (risk of severe hypocalcaemia is 8% and 5% for denosumab and zoledronic acid, respectively [First-line treatment for mCRPC will be influenced by which treatments were used when metastatic cancer was first discovered.No clear-cut recommendation can be made for the most effective drug for first-line CRPC treatment (i.e. Both tests are intended to reduce the number of unnecessary prostate biopsies in PSA-tested men. It should be at least 66 Gy to the prostatic fossa (plus/minus the base of the seminal vesicles, depending on the pathological stage after RP) [Salvage RT is also associated with toxicity. Publication type. continuous vs. interrupted, or single-needle vs. double-needle running suture). A 3 to 6-month testosterone level assessment has been suggested to ensure castration is achieved and maintained. This leads to an unchanged or slightly elevated testosterone level. Microscopic bladder neck invasion is considered EPE.

*Only studies reporting survival outcomes as primary end-points have been included.ARTA = androgen receptor targeting agents; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; FU = follow-up; HR = hazard ratio; mo = months OS = overall survival; OR = odds ratio; ORR = objective response rate; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival; yr = year.All patients who receive treatment for mCRPC will eventually progress.
of Pages 4 disease and prostate-specific antigen characteristics.